We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Potential Microbial Markers Identified for Cervical Pre-Cancer Progression

By LabMedica International staff writers
Posted on 08 Apr 2020
Human papillomavirus (HPV) infection is one of the most common sexually transmitted infections. More...
However, only a small percentage of high-risk (HR) HPV infections progress to cervical pre-cancer and cancer. The role of the cervicovaginal microbiome (CVM) in the natural history of HR-HPV has been investigated.

Persistent cervical infections by high-risk (HR) human papillomavirus (HPV) cause virtually all cervical cancers and their immediate precursor lesions. Most sexually active women have been infected with HPV at some point in their lives and in the vast majority the infection is cleared within a few months

An international team of scientists led by those at the Albert Einstein College of Medicine (Bronx, NY, USA) have identified potential microbial markers of cervical pre-cancer progression or clearance in women with high-risk human papillomavirus (HPV) infections. The team investigated the role of the CVM in the natural history of HR-HPV. The study included women aged 18–25 years of age and cervical samples from two visits of 273 women with an incident HR-HPV infection were used to evaluate the prospective role of the CVM on the natural history of HR-HPV. The CVM was characterized by amplification and sequencing the bacterial 16S V4 rRNA gene region and the fungal ITS1 region using an Illumina MiSeq platform (Illumina, San Diego, CA, USA).

The scientists used the 16S and fungal ITS1 sequences found in the cervicovaginal samples at each time point, together with HPV infection clearance, persistence, or progression to cervical neoplasia grade 2 (CIN2+) or grade 3 (CIN3+) lesion, the team relied on advanced epidemiological modeling and other analysis to uncover the proposed Gardnerella biomarker.

The investigators reported that Gardnerella appeared to be more common in women with infections that progressed to pre-cancerous CIN2+ lesions, as was enhanced microbial diversity. Their follow-up studies suggested that rising Gardnerella in microbiomes of at-risk patients reflected increased cervicovaginal diversity driven by pre-cancerous progression.

The authors concluded that the results of their study suggested a novel association between the effect of Gardnerella and disruption of CVM homeostasis that can influence the pathway of HR-HPV infection progression to cervical pre-cancer. They further showed the interplay between several key components of the cervicovaginal microbiome and demonstrate that within the context of HR-HPV natural history the effect of Gardnerella is mediated by increased cervicovaginal bacterial diversity directly preceding the progression of a persistent infection to pre-cancer. The study was published on March 26, 2020 in the journal PLOS Pathogens.

Related Links:
Albert Einstein College of Medicine
Illumina



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The approach uses in-house pathology tests and streamlined access to specialists to shorten the diagnostic pathway for children with immune conditions. (Image Credit: iStock)

Streamlined Genetic Testing Speeds Pediatric Immune Disorder Diagnosis

Children with genetic immune conditions can develop life-threatening illness, unusual infections, or autoimmune problems before the underlying cause is identified. More than 500 of these rare disorders... Read more

Immunology

view channel
Image: Acute myeloid leukemia is the first of several disease areas the collaborators plan to pursue together as part of efforts to advance precision diagnostics (Image Credit: Adobe Stock)

Immune Profiling Initiative Aims to Improve Bone Marrow Analysis in Leukemia

Acute myeloid leukemia (AML) is an aggressive blood cancer in which assessing disease burden after therapy can help guide clinical evaluation. Patients with measurable residual disease (MRD) after treatment... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.